IP Library › Granted Patent US 11,191,803
Granted Patent B2
US 11,191,803 · App. 16/477,092 · Granted Dec 7, 2021

Laminin receptor peptides for therapy

Inventor: Arpi Rogers (London, GB)
A61K38/10A61K38/177A61P21/00A61P25/28C07K7/08C07K14/00C07K14/4748
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,191,803
App. No.
16/477,092
Granted
Dec 7, 2021
Kind
B2
Abstract

The present invention relates, to a laminin receptor peptide for use in the treatment of amyotrophic lateral sclerosis (ALS), which is also known as Motor Neurone Disease (MND) and can include Frontotemporal Dementia (FTD). The invention also encompasses the laminin receptor peptide, nucleic acids encoding the laminin receptor peptide, vectors comprising the nucleic acids and compositions comprising the laminin receptor peptide.

Claims (20)

1. A peptide multimer comprising two or more peptide molecules, wherein:

(a) each of the two or more peptide molecules comprise the amino acid sequence of SEQ ID NO: 1; or

(b) each of the two or more peptide molecules comprise an amino acid sequence having at least 80% identity to the sequence of SEQ ID NO: 1;

and wherein the peptide multimer does not comprise a contiguous sequence of amino acids found in the laminin receptor (SEQ ID NO: 6) other than SEQ ID NO: 1.

2. A fusion protein comprising the peptide multimer of claim 1 .

3. A composition comprising the peptide multimer of claim 1 and a pharmaceutically acceptable excipient.

4. A syringe comprising the composition of claim 3 .

5. The peptide multimer of claim 1 , wherein the peptide multimer comprises the sequence of SEQ ID NO: 3.

6. The peptide multimer of claim 5 , wherein the peptide multimer consists of the sequence of SEQ ID NO: 3.

7. The peptide multimer of claim 1 , wherein the peptide multimer is a peptide dimer comprising two peptide molecules, wherein:

(a) each of the two peptide molecules comprise the amino acid sequence of SEQ ID NO: 1; or

(b) each of the two peptide molecules comprise an amino acid sequence having at least 80% identity to the sequence of SEQ ID NO: 1.

8. The peptide dimer of claim 7 , wherein the two peptide molecules are linked by a disulphide bridge.

9. The peptide dimer of claim 8 , wherein the disulphide bridge is located at the amino-terminus of each peptide molecule.

10. A nucleic acid encoding the peptide of claim 1 .

11. A vector comprising the nucleic acid of claim 10 .

12. A peptide comprising the amino acid sequence of SEQ ID NO: 2.

13. The peptide of claim 12 , wherein the peptide consists of the sequence of SEQ ID NO: 2.

14. A peptide dimer comprising two peptide molecules of claim 12 .

15. The peptide dimer of claim 14 , wherein the two peptide molecules are linked through a disulphide bridge formed from the amino-terminal cysteine residue of each peptide molecule.

Priority Claims (1)
GB 1700529 · Jan 12, 2017 · national
Continuity (1)
Related Publication 20190343915A1 · Nov 14, 2019